BMJ  2004;328:1217 (22 May), doi:10.1136/bmj.328.7450.1217

News

Pfizer pleads guilty, but drug sales continue to soar

New York

The first 150 words of the full text of this article appear below.

Pfizer, the world's largest drug maker, pleaded guilty on 13 May to numerous civil and criminal charges for illegally promoting the off-label use of gabapentin (Neurontin). It has agreed to pay a $240m (£136m; 200m) criminal fine and $152m to state and federal healthcare programmes. The fine is the second largest given in the industry.

Meanwhile, off-label sales of gabapentin continue to soar, despite evidence that the drug is not effective for some of the problems it is used to treat.

David Franklin, 42, a microbiologist and former Harvard research fellow who worked as a "medical liaison" expert for Warner-Lambert before it was bought by Pfizer in 2002, filed a whistleblower suit under the False Claims Act in 1996, charging the company with using "fraudulent scientific evidence" to promote off-label uses of gabapentin.

Dr Franklin's suit detailed how the company suppressed study results, planted people in medical audiences to ask . . . [Full text of this article]

-->
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

FDA oversight of drug company promotion of off-label use is poor, US watchdog says

Janice Hopkins Tanne
BMJ 2008 337: a1163. [Extract] [Full Text]

Poverty, health, and the role of doctors

Bassem Saab and Jumana Antoun
BMJ 2006 332: 860. [Extract] [Full Text]

More surveillance of drugs is needed to protect public

Lynn Eaton
BMJ 2004 329: 1124. [Extract] [Full Text]

Whistleblower charges medical oversight bureau with corruption

Jeanne Lenzer
BMJ 2004 329: 69. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Hodgson, R., Bushe, C., Hunter, R. (2007). Measurement of long-term outcomes in observational and randomised controlled trials. Br. J. Psychiatry 191: s78-s84 [Abstract] [Full text]  
• Markman, J. D. (2006). Gabapentin in the operating room: clear for discharge?. Neurology 67: 1116-1117 [Full text]  
• Hodgson, R., Belgamwar, R. (2006). Off-label prescribing by psychiatrists. Psychiatr. Bull. 30: 55-57 [Abstract] [Full text]  
• Dzik, W. H. (2006). Off-label Reports of New Biologics: Exciting New Therapy or Dubious Research? Examples From Recombinant Activated Factor VII. J Intensive Care Med 21: 54-59  

Online poll

Find out more here>> and here>>